Abstract
Clear cell renal cell carcinoma (ccRCC) is the most common renal cell carcinoma and has poor prognosis in the locally advanced stage. Ferroptosis, a relatively new type of cell death, has gained significant attention in recent years. This study aimed to explore the prognostic value of ferroptosis-related genes (FRGs) in ccRCC. In this study, 50 differentially expressed FRGs between ccRCC and adjacent normal kidney tissues were identified, 26 of them correlated with overall survival (OS) (P <0.05). Eight optimal FRGs were selected by Lasso regression and multivariate Cox regression analysis, and used to construct a new prognostic risk signature to predict the prognosis of ccRCC patients. In addition, the signature passed the validation of prognostic survival analyses by a significant margin, and the risk score was identified as an independent prognostic marker via Cox regression analyses. Further studies indicated that the signature was significantly correlated with immune cell infiltration. Moreover, the levels of eight FRGs were examined in ccRCC. Collectively, the 8-FRG prognostic risk signature helps the clinicians predict the prognosis and OS of the patients, and standardize prognostic assessments.
Highlights
Renal cancer accounts for approximately 2–3% of the adult malignancies and 80–90% of the adult renal malignancies [1]
Through the protein–protein interaction (PPI) network, we found that ACACA, FTH1 and HMGCR may be the hub genes (Figure 3A)
The abnormal ferroptosis-related genes (FRGs) are reported to be involved in the initiation and progression of Clear cell renal cell carcinoma (ccRCC) [12, 25]
Summary
Renal cancer accounts for approximately 2–3% of the adult malignancies and 80–90% of the adult renal malignancies [1]. 80% of the RCC cases are Clear cell renal cell carcinoma (ccRCC) [2]. Often asymptomatic in the early stages, ccRCC is suspected when the tumor volume increases and the patient develops fever, fatigue and other systemic symptoms [3]. The microscopic appearance is often confused with granular cell carcinoma and spindle cell carcinoma, which makes it very difficult to grade under microscope [4]. Recent studies have shown that high-risk ccRCC patients treated with the active drugs have no significant changes in the overall survival (OS) [5]. To monitor the disease progression, the scientific community should explore novel and effective biomarkers for ccRCC prognosis, including the new prognostic signatures
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
